Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)

Pleural Empyema Clinical Trial

Official title: Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)

Status Completed

Clinical Trial Summary

Bacterial pneumonia can be complicated by the development of excess fluid and pus (pleural empyema) around the lungs in children. The incidence of pleural empyema in children has increased significantly in the last 10 years.

Short term morbidity for this condition is substantial, but unlike in adults, the long term outcome of this condition for children in developed countries is favourable. Inserting a chest drain and then adding a medicine (tissue plasminogen activator - tPA) to break down organized pus has been shown to be an effective therapy for reducing the duration of illness. However, this treatment is still suboptimal and prolonged hospitalization is common. Recent data from adults suggests that adding an additional medicine (DNase) to decrease the viscosity (thickness) of the fluid improves drainage and leads to better patient outcomes; however, there are no published studies on children.

This is a multi-centre randomized controlled trial comparing the time to discharge from hospital after chest drain insertion in previously well children who present with pleural empyema, treated with intrapleural DNase and tissue plasminogen activator (tPA) by chest drain for three doses over 48 hours compared with three doses over 48 hours of tPA alone. Other outcomes related to effectiveness, safety and cost will be assessed as well.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Empyema
• Empyema, Pleural
• Pleural Empyema

• NCT number: NCT01717742
• Study type: Interventional
• Source: The Hospital for Sick Children
• Status: Completed
• Phase: Phase 3
• Start date: December 2012
• Completion date: December 2017